TABLE 1.
Study design
| Treatment | Groupa | Useb of:
|
|||||
|---|---|---|---|---|---|---|---|
| P4 | Gamma globulin | Ceftriaxone
|
|||||
| 3,000 μg | 300 μg | 3.0 μg | 0.3 μg | ||||
| Combination therapy | 1 | − | − | − | − | − | − |
| 2 | + | − | − | − | − | − | |
| 3 | − | + | − | − | − | − | |
| 4 | − | − | + | − | − | − | |
| 5 | − | − | − | + | − | − | |
| 6 | − | − | − | − | + | − | |
| 7 | − | − | − | − | − | + | |
| 8 | + | + | − | − | − | − | |
| 9 | + | + | − | + | − | − | |
| 10 | + | + | − | − | + | − | |
| 11 | + | + | − | − | − | + | |
| Repeat therapy | 10 | + | + | − | − | + | − |
a
n = 10/group. All groups received S. pneumoniae serotype 3 (WU2) intranasally at ∼2.1 × 107 cells/40 μl/mouse.
b
P4 at 50 μg in a 100-μl volume and 100 μl of gamma globulin were administered i.v.; ceftriaxone was administered i.p. at the indicated doses in a 100-μl volume. +, included in the therapeutic mixture; −, not included in the therapeutic mixture.